| RETARGETED ONCOLYTIC HSV | |||||||
|---|---|---|---|---|---|---|---|
| gB | gC | gD | gH/gL | ||||
| A. Fusogenic membrane glycoproteins (FMGs) | |||||||
| 25 | DUs3-8 | − | − | HveA−/HveC− * | − | VSV-G | Preclinical |
| 26 | Amplicon VSV-G | Δ gB | − | − | − | VSV-G | Preclinical |
| B. Peptide ligands | |||||||
| 27 | KgBpK:-gC-EPO | HS− | HS− * | − | − | full-length erythropoietin hormone EPO | Preclinical |
| 28 | KgBpK-:gC-preS1 | HS− | HS− * | − | − | HBV-sAg | Preclinical |
| 29 | R5111 | HS− | HS− * | HveA+/HveC+ * | − | IL-13 | Preclinical |
| 30 | R5141 | HS− | HS− * | HveA−/HveC− * | − | IL-13 | Preclinical |
| 31 | R5181 | HS− | HS− *1 | HveA+/HveC+ *2 | − | IL-13*1and uPA*2 | Preclinical |
| 32 | AmpliconpCONGA-H | − | HS− * | − | − | HIS-tag | Preclinical |
| 33 | Amplicon pCONGA-MG11 | − | HS− * | − | − | MG11 peptide | Preclinical |
| 34 | AmplicongC-BDNF | HS− | HS− * | − | − | pre-pro BDNF | Preclinical |
| 35 | AmplicongC-GDNF | HS− | HS− * | − | − | pre-pro GDNF | Preclinical |
| 36 | Amplicon NMDA NR2A/2B | HS− | HS− * | − | − | NMDA NR2A/B Ab | Preclinical |
| C. Single chain antibodies (scFvs) | |||||||
| 37 | KGNEp | NA | − | HveA−/HveC− * | − | scFvEpCAM | Preclinical |
| 38 | KGNE | NA | − | HveA−/HveC− * | − | scFv EGFR | Preclinical |
| 39 | KGNC | − | − | HveA−/HveC− * | − | scFv CEA | Preclinical |
| 40 | R-LM113 | − | − | HveA−/HveC+ * | − | scFv HER2 | Preclinical |
| 41 | R-LM249 | − | − | HveA−/HveC− * | − | scFv HER2 | Preclinical |
| 42 | R-VG809 | − | − | HveA−/HveC− * | −* | scFv HER2 | Preclinical |
| 43 | R-LM31 | − | − | −* | − | scFv HER2 | Preclinical |
| 44 | R-LM11 | − | − | HveA−/HveC+ * | − | scFv HER2 | Preclinical |
| 45 | R-LM39 | − | − | HveA−/HveC+ * | − | scFv HER2 | Preclinical |
| 46 | HSV1716 scFv CD55 | − | − | HveA−/HveC− * | − | scFv CD55 | Preclinical |
| 47 | Amplicon pCONGA-MR1-1 | HS− | HS− * | − | − | scFv EGFR MR1-1 | Preclinical |
| D. Adapters | |||||||
| 48 | HVEM: CEA Adapter | − | − | − | − | scFv CEA | Preclinical |
| 49 | Nectin1: EGFR Adapter | − | − | − | − | scFv EGFR | Preclinical |
| 50 | Nectin1 Adapter | − | − | − | − | nectin1-HveC | Preclinical |
Transgene molecule inserted
Imlygic™
−Wild type
RAMBO, Rapid Antiangiogenesis Mediated By Oncolytic virus; HVEM:CEA, Herpes Virus Entry Mediator; Carcino Embryonic Antigen; TK, Thymidine Kinase; OS, OncSyn; HS, Heparan Sulfate; HveA, Herpes Virus Entry Mediator A; HveC, Herpes Virus Entry Mediator C; gB, glycoprotein B; gC, glycoprotein C; gD, glycoprotein D; gH/gL, glycoprotein H/L; IL4, Interleukin 4; IL10, Interleukin 10; IL12-Interleukin 12; IL13, Interleukin 13; GM-CSF, Granulocyte Macrophage Colony Stimulating Factor; IL18, Interleukin 18; PF4, Platelet Factor 4; TSP-1, Thrombospondin-1; Vstat, Vasculostatin; 15-PGDH, 15-Prostaglandin Dehydrogenase; yCD, yeast Cytosine Deaminase; GALV.fus, gibbon ape leukemia virus envelope fusogenic glycoprotein; EGFP, enhanced green fluorescent protein gene; VSV-G, vesicular stomatitis virus glycoprotein G; EPO, Erythropoietin; EGFR, Epidermal Growth Factor Receptor; ICP, Infected Cell Protein.